TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06260527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARTS-011
Description: Single ascending dose (SAD): 3mg, 10mg, 20mg, 40mg, and 60mg. Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days. Food effect study: single dose of ARTS-011 under the fasting and high-fat meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARTS-011
Description: Single ascending dose (SAD): 3mg, 10mg, 20mg, 40mg, and 60mg. Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days. Food effect study: single dose of ARTS-011 under the fasting and high-fat meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days. Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days. Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days.
Study: NCT05892081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Colloidal oatmeal
Description: The colloid oatmeal had the following component: Colloidal Oat (5gm), stearic acid 5, cretoctryl alcohol 2.5, cetyl alcohol 2.5, koh 02, potassium sorbate 1gm, paraffin oil 5ml, and soft paraffin 10gm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cold cream
Description: It is composed of stearic acid 5, cretoctryl alcohol 2.5, cetyl alcohol 2.5, koh 02, potassium sorbate 1gm, paraffin oil 5ml, and soft paraffin 10gm
Study: NCT04516902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide
Description: A moderate dose of 100 μg LSD will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide
Description: A moderate dose of 100 μg LSD will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-methylenedioxymethamphetamine
Description: A moderate dose of 100 mg MDMA will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-methylenedioxymethamphetamine
Description: A moderate dose of 100 mg MDMA will be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LSD Placebo
Description: Pure alcohol instead of an alcoholic solution containing LSD

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LSD Placebo
Description: Pure alcohol instead of an alcoholic solution containing LSD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MDMA Placebo
Description: Mannitol capsules instead of capsules containing MDMA

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MDMA Placebo
Description: Mannitol capsules instead of capsules containing MDMA
Study: NCT05910593

Intervention type: DIAGNOSTIC_TEST
Intervention: Dexterity Assessment Tool
Description: Measures finger dexterity using pressure sensor pads.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dexterity Assessment Tool
Description: Measures finger dexterity using pressure sensor pads.
Study: NCT06480045

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Performed PECS II block with AI integrated USG
Description: A 4-year anesthesiology resident, under the supervision of two senior anesthesiologists, performed a PECS II block with AI-integrated USG.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Performed PECS II block with conventional USG
Description: A 4-year anesthesiology resident, under the supervision of two senior anesthesiologists, performed a PECS II block with conventional USG.
Study: NCT06046508

Intervention type: OTHER
Intervention: blood samples collection
Description: patients, who meet all the inclusion criteria and none of the exclusion criteria, will be enrolled and they will perform a blood withdrawal before PFO correction and 180 days after the intervention
Study: NCT04573777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repatha
Description: 140 MG in 1 ML Prefilled Syringe PCSK9 Inhibitor
Study: NCT04462042

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiotherapy
Description: Proton radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon radiotherapy
Description: Conventional photon radiotherapy
Study: NCT06513260

Intervention type: PROCEDURE
Intervention: Surgical extraction of impacted lower third molars.
Description: Surgical extraction of impacted mandibular third molars in the mesioangular position, according to the Tetsch and Wagner classification

Intervention type: PROCEDURE
Intervention: Surgical extraction of impacted lower third molars.
Description: Surgical extraction of impacted mandibular third molars in the mesioangular position, according to the Tetsch and Wagner classification
Study: NCT05600712

Intervention type: DEVICE
Group type: OTHER
Intervention: REDAPT Sleeved Stem
Description: The REDAPT Sleeved Stem is designed to provide secondary proximal support to the distal fixation and enhance implant stability.
Study: NCT05382325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-1484
Description: Subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-1484
Description: Subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion
Study: NCT06323720

Intervention type: OTHER
Intervention: Quantitative Sensory Testing
Description: Assessment of the heat and cold pain thresholds, temporal summation, conditioned pain modulation, pressure pain thresholds, electrical pain thresholds, and withdrawal reflex.

Intervention type: OTHER
Intervention: Quantitative Sensory Testing
Description: Assessment of the heat and cold pain thresholds, temporal summation, conditioned pain modulation, pressure pain thresholds, electrical pain thresholds, and withdrawal reflex.

Intervention type: OTHER
Intervention: Quantitative Sensory Testing
Description: Assessment of the heat and cold pain thresholds, temporal summation, conditioned pain modulation, pressure pain thresholds, electrical pain thresholds, and withdrawal reflex.
Study: NCT06260839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance neurography
Description: preoperative magnetic resonance neurography and assisted design of surgical approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no magnetic resonance neurography
Description: Preoperative magnetic resonance neurography was not performed, and general minimally invasive surgery was performed
Study: NCT04119908

Intervention type: DEVICE
Group type: OTHER
Intervention: Sublingual videomicroscopy
Description: Measurement of sublingual capillary density by video microscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sublingual videomicroscopy
Description: Measurement of sublingual capillary density by video microscopy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: Collection of citrate tubes of 5 mL at baseline and at 36 months
Study: NCT05739617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Respiratory Training Exercise Program
Description: This comprehensive respiratory training exercise program consists of four main components, including oropharyngeal muscle training, respiratory muscle training, aerobic exercise, and sleep hygiene education.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sleep hygiene education
Description: Sleep hygiene education
Study: NCT04785885

Intervention type: DIAGNOSTIC_TEST
Intervention: iStat Handheld Blood Analyzer
Description: An easy-to-use blood analyzer that provides monitoring of heparin anticoagulation quickly for point-of-care testing. Testing will be done at baseline, 30s, 90s and 180s after heparin administration.

Intervention type: DIAGNOSTIC_TEST
Intervention: iStat Handheld Blood Analyzer
Description: An easy-to-use blood analyzer that provides monitoring of heparin anticoagulation quickly for point-of-care testing. Testing will be done at baseline, 30s, 90s and 180s after heparin administration.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hemochron
Description: An easy-to-use blood analyzer that provides monitoring of heparin anticoagulation quickly for point-of-care testing. Testing will be done at baseline, 30s, 90s and 180s after heparin administration.
Study: NCT05347654

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local treatment with silver sulphadiazine only
Description: Local treatment with silver sulphadiazine and tulle from day 0 to day 8 (included). From the 9th day and until healing, the dressings are made with tulle, every 48 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local treatment with silver sulphadiazine followed by URGOCLEAN® dressing
Description: Local treatment of silver sulphadiazine with tulle from day 0 to day 4, then with URGOCLEAN® dressing every 48h from day 5 to day 8. From the 9th day and until healing, the dressings are made with tulle, every 48 hours.
Study: NCT04785885

Intervention type: DIAGNOSTIC_TEST
Intervention: Hemochron
Description: An easy-to-use blood analyzer that provides monitoring of heparin anticoagulation quickly for point-of-care testing. Testing will be done at baseline, 30s, 90s and 180s after heparin administration.
Study: NCT05041543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTX-101
Description: Eye drops, topical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTX-101
Description: Eye drops, topical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTX-101
Description: Eye drops, topical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTX-101
Description: Eye drops, topical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTX-101
Description: Eye drops, topical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo as eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo as eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo as eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo as eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo as eye drops
Study: NCT05110586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrotherapy
Description: Applications will be applied for 4 weeks, 5 days a week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrotherapy
Description: Applications will be applied for 4 weeks, 5 days a week
Study: NCT04977505

Intervention type: DEVICE
Intervention: pushlock
Description: The surgery procedure was performed with pushlock for fixation

Intervention type: DEVICE
Intervention: gryphon
Description: The surgery procedure was performed with Gryphon for fixation
Study: NCT06509516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Sleeper-Stretch
Description: Self-administered stretch in which the individual remains side-lying on the upper limb to be stretched, keeping the scapula stabilized by his/her own weight, and rolls the trunk 20-30º posteriorly, maintaining a 90º flexion in the shoulder and elbow. Using the opposite hand over the forearm of the limb to be stretched, the individual passively brings the shoulder to maximum internal rotation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Sleeper-Stretch
Description: Self-administered stretch in which the individual remains side-lying on the upper limb to be stretched, keeping the scapula stabilized by his/her own weight, and rolls the trunk 20-30º posteriorly, maintaining a 90º flexion in the shoulder and elbow. Using the opposite hand over the forearm of the limb to be stretched, the individual passively brings the shoulder to maximum internal rotation.
Study: NCT06211283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Description: fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Description: fasted

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium valproate
Description: fasted

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium valproate
Description: fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Description: fed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Description: fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium valproate
Description: fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium valproate
Description: fed
Study: NCT05047393

Intervention type: OTHER
Intervention: Current blood vitamin D level and painDetect questionairre score will be detected
Description: PainDETECT neuropathic pain questionnaire will be used to evaluate the presence of nociceptive, mixed and neuropathic pain in patients. Patients with a total questionnaire score of 12 or less are considered nociceptive pain without a neuropathic pain component. If the total score is in the range of 13-18, the result is uncertain, but it is accepted that the neuropathic component can be found in the mixed type, and in the scores of 19 and above, it is accepted that the neuropathic pain component is present. Patients with previously obtained and finalized vitamin D levels \< 20 ng/mL, 20-30 ng/mL, and ˃30 ng/mL will be grouped as deficiency, insufficiency and normal, respectively.
Study: NCT05684731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KM1
Description: Administer via intraperitoneal infusion for 3 or 6 doses Q3D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Physician's Choice of carboplatin (preferred) or cisplatin，gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin，with or without bevacizumab.~Administer beginning in Week 5 or Week 6.
Study: NCT05857423

Intervention type: OTHER
Group type: OTHER
Intervention: Gentle Human Touch
Description: Gentle Human Touch procedure has 3 step as follows:~1. Mother/nurse must wash their hands with antimicrobial soap for 3 minutes before starting Gentle Human Touch procedure.~2. Next, mother/nurse must warm their hands.~3. Mother/nurse must place their one hand on the infant's head and the other hand on the lower abdomen that covers the waist and hips of the preterm infant, for 15 minute.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gentle Human Touch
Description: Gentle Human Touch procedure has 3 step as follows:~1. Mother/nurse must wash their hands with antimicrobial soap for 3 minutes before starting Gentle Human Touch procedure.~2. Next, mother/nurse must warm their hands.~3. Mother/nurse must place their one hand on the infant's head and the other hand on the lower abdomen that covers the waist and hips of the preterm infant, for 15 minute.
Study: NCT05886517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transfemoral transcatheter aortic valve implementation
Description: ranscatheter aortic valve implantation, a percutaneous treatment for severe aortic valve stenosis, is increasingly performed worldwide. The pacemaker should be able to perform overdrive pacing which is essential to reduce cardiac output and transvalvular blood flow which are critical during balloon aortic valvuloplasty and valve deployment of the balloon- expandable valve. Minor adjustment may be needed for ideal positioning, but importantly this has to be done before valve implantation
Study: NCT05769127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program (DPP), Diabetes Self-Management Training (DSMT)
Description: DPP lifestyle intervention program DSMT education on diabetes and lifestyle changes
Study: NCT05001503

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stability UO
Description: STABILITY UO is a standalone software, based on a Bayesian model, which quantifies the risk of an individual patient developing severe oliguria (0.3mg/kg/hr for 6 hours). The model identifies at risk patients by predicting future urine output, using only previously recorded urine output values for that individual, allowing clinicians to see the predicted risk of a patient developing severe oliguria in real time.
Study: NCT06559280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esketamine
Description: During the operation, 0.25mg/kg esketamine was induced, and 1mg/kg esketamine was added to the postoperative analgesia pump
Study: NCT06547294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osprey IV
Description: Utilization of novel needle over catheter commercial insertion device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Historical Controls
Description: Outcome rates from catheter over needle devices (traditional manner of inserting peripheral IV)
Study: NCT05562778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chatbot
Description: A chatbot is a software program designed to simulate human conversation, typically via text. Chatbots utilize natural language processing to gather patient data, anticipate questions, and predict responses. In this study, the Chatbot will simulate a text-like conversation with patients via a smartphone and use this platform to deal with the time-consuming nature of family history collection. The chatbots can then triage the collected family history against medical guidelines to determine which patients warrant genetic testing. For those patients meeting criteria for genetic testing, the chatbot can offer pre-test education and assist physicians with ordering genetic testing for interested patients meeting high-risk criteria.
Study: NCT04905082

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: View HOPE-Genomics tool after genomic test results are available
Study: NCT06028529

Intervention type: DEVICE
Group type: OTHER
Intervention: Exoskeleton
Description: lightweight ground exoskeleton
Study: NCT04963153

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Given IV
Study: NCT04905082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: View HOPE-Genomics before sequencing results are available
Study: NCT04963153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan
Study: NCT04905082

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Genomic Profile
Description: Receive genomics test results
Study: NCT04784871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5waysA Intervention
Description: Web-based 10 week intervention, encouraging participants engaging in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 5waysA Active wait-list control
Description: Writing activity log in the waiting time. Then, after five months and the writing of activity log, the participants get the web-based intervention and SMS massages, which encourage the participants to engage in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
Study: NCT04909034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-20
Description: Fermented soybean extract MicrSoy-20(MS-20), which uses a variety of lactic acid bacteria and yeasts to metabolize organic soybeans

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution without active ingredients
Study: NCT04784871

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 5waysA Inactive wait-list control
Description: No activity while the participants wait. After five months of waiting, the participants get the web-based intervention and SMS messages, which encourage participants engage in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
Study: NCT05992896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome
Description: Injection into pelvic area and into the edges of wound at the end of the procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Looks exactly like the study drug, but contains no active ingredients. Injection into pelvic area and into the edges of wound at the end of the procedure .
Study: NCT06233942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG-C9074
Description: administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG-C9074
Description: administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG-C9074
Description: administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG-C9074
Description: administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: administered by intravenous infusion
Study: NCT04905082

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT06157268

Intervention type: OTHER
Intervention: Natural history and non therapeutical therapy
Description: This study concerns a natural history study part and a muscle fatigability part.~For the natural history study no interventions will be used. For the muscle fatigability part non therapeutical therapies will be used. This includes endurance tests, isokinetic dynamometry and repetitive nerve stimulation.

Intervention type: OTHER
Intervention: Natural history and non therapeutical therapy
Description: This study concerns a natural history study part and a muscle fatigability part.~For the natural history study no interventions will be used. For the muscle fatigability part non therapeutical therapies will be used. This includes endurance tests, isokinetic dynamometry and repetitive nerve stimulation.

Intervention type: OTHER
Intervention: Natural history and non therapeutical therapy
Description: This study concerns a natural history study part and a muscle fatigability part.~For the natural history study no interventions will be used. For the muscle fatigability part non therapeutical therapies will be used. This includes endurance tests, isokinetic dynamometry and repetitive nerve stimulation.